How long before vivelle dot works
Protein C, protein S, or antithrombin deficiency or other thrombophilias. Breast or other estrogen-dependent neoplasms. Hepatic impairment or disease. Increased risk of endometrial carcinoma or hyperplasia in women with intact uterus adding progestin is essential.
Not for prevention of cardiovascular disease or dementia. Increased risk of cardiovascular disorders eg, stroke, DVT ; discontinue if occurs or suspected. Manage risk factors for cardiovascular disease and venous thromboembolism appropriately. Discontinue at least 4—6 weeks before surgery type associated with increased risk of thromboembolism or during prolonged immobilization. Increased risk of breast or ovarian cancer. Gallbladder disease. Bone disease associated with hypercalcemia.
Visual abnormalities. Pre-existing hypertriglyceridemia. History of cholestatic jaundice. Discontinue if cholestatic jaundice, pancreatitis, hypercalcemia, or retinal vascular lesions occur. Monitor thyroid function. Monitor conditions aggravated by fluid retention eg, cardiac or renal impairment ; discontinue if medically concerning fluid retention. Hereditary angioedema. Hepatic hemangiomas.
Do initial complete physical and repeat annually include Pap smear, mammogram, BP. Pregnancy: not indicated. Nursing mothers. May be potentiated by CYP3A4 inhibitors eg, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, and grapefruit juice.
Concomitant thyroid replacement; may need to increase thyroid dose. The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer. The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older.
Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia. Start therapy with Vivelle-Dot 0. Dosage adjustment should be guided by the clinical response.
The effectiveness of Vivelle for the prevention of post-menopausal osteoporosis was evaluated in a two-year, double-blind, randomized, placebo-controlled, parallel-group study. The trial included a total of hysterectomized and non-hysterectomized , surgically or naturally menopausal women with no evidence of osteoporosis. One hundred ninety-four of the subjects were randomized to receive one of four doses of Vivelle 0.
Over two years, the study systems were applied to the buttock or the abdomen twice a week. All doses of Vivelle were significantly superior to placebo at all time points, with the exception of Vivelle 0.
A secondary efficacy measurement in the trial was an analysis of percent change from baseline in femoral neck BMD. Results showed that all doses of Vivelle were significantly superior to the placebo at 24 months.
Additionally, the highest dose of Vivelle was more effective than the placebo at all time points. In two controlled clinical trials of subjects, two dose levels of Vivelle were tested. The 0. An additional week placebo-controlled study in patients was performed to test the lowest dose of 0.
The Vivelle system's possible benefits in the prevention of postmenopausal osteoporosis have also been examined. A 2-year double-blind, randomized, placebo-controlled parallel group study was conducted with a total of individuals.
The enrolled group consisted of hysterectomized and non-hysterectomized , surgically or naturally menopausal women within 5 years of menopause , with no evidence of osteoporosis. All Vivelle doses were significantly superior to a placebo at all time points with the exception of Vivelle 0.